Mimopath®-based Vaccines

In addition to the intranasal Mimopath®-based influenza vaccine, our scientists and collaborators have demonstrated in animal models that Mimopath-based vaccines also protect against live parasites (malaria) and bacteria (Streptococcus pneumonia, Yersinia pestis). Moreover, Mimopath®-based vaccines were shown to be effective both as an injectable and an intranasal vaccine. This forms the basis for a broad application of this new and innovative vaccine technology

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >

21.03.11 Mucosis starts clinical study with its lead product, Flugem®
more >

12.11.10 Dr. Barry Buckland joins the Mucosis supervisory board
more >

28.09.10 Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines
more >